Biocon Ltd, a biopharmaceutical company, has signed a licensing agreement with Janssen Sciences Ireland to enable the commercialisation of Yesintek, its proposed biosimilar to Stelara (ustekinumab), in nine additional markets with immediate effect. The agreement covers Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan, expanding Biocon’s potential reach in the […]